Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug classes in Europe since 2011. Although laser photocoagulation has long been the standard of care for patients with the most advanced stages of DR, recent clinical trial results suggest that intravitreal pharmacotherapy injections may be effective treatment for this broader patient population as well. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the United States and EU5 markets for DR and DME. The Diabetic Retinopathy/Diabetic Macular Edema | Current Treatment | EU detailed, expanded analysis offers a snapshot of how ophthalmologists in the EU5 are currently treating DR and DME patients, with a particular focus on use of intravitreal vascular endothelial growth factor (VEGF) inhibitors and intravitreal corticosteroid implants, as well as insight into the factors driving such prescribing habits. 

Table of contents

  • Detailed, Expanded Analysis (EU)
    • Physician Prescribing Practices
      • Key Findings
      • Patient Characteristics
        • Bilateral Retinopathy Is Common for DR and DME Patients
      • Treatment Practices
        • Approved VEGF Inhibitors Dominate DME Treatment in the EU5
        • Time to Treatment Start
        • Treatment Rates
        • Patient Share by Product
        • Treatment Duration by Product
        • Use of Nonpharmacological Approaches
        • Line of Therapy Analysis
        • Combination/Regimen/Co-Medication Analysis
      • Persistency and Compliance
        • Compliance Is Equally High in the EU5 for Each IVT Pharmacotherapy Administered for DME
      • Sequencing of Treatment
        • Current Eylea-Treated Patients Are Often Treatment-Naive at Agent Initiation
      • Recent/Anticipated Changes in Brand Usage/Treatment Approach
        • Eylea's Patient Share Among DME Patients Is Expected to Continue to Grow One Year From Now
    • Physician Insight on Medical Practice
      • Key Findings
      • Drivers of Treatment Selection
        • Efficacy and Product Access Drive Prescribing Decisions in DME
        • Factors Influencing Treatment and Disease Management
        • Major Drivers of Brand Usage/Treatment
        • Major Obstacles for Brand Usage/Treatment
        • Rationale for Treatment Switching by Therapy/Approach
        • Rationale for Therapy Discontinuation
        • Rationale for Treatment Deferral by Therapy/Approach
      • Face-to-Face Product Detailing Effectiveness
        • Opportunity Exists for DME Brand Differentiation During Detailing Vistis
        • Sales Representative Frequency and Reach
        • Sales Representative Satisfaction
        • Message Recall
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Primary Market Research

Author(s): Emma McFadden, PhD; Margaret M. Weigel

Emma McFadden, is a  Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and ; Prior to joining Decision Resources Group, Emma earned a in neuroscience and a in biochemistry from Trinity College Dublin.  

Margaret Weigel, is a Business Insights Analyst on the CNS/Ophthalmology Disorders team at Decision Resources Group. Her specialties are diabetic retinopathy/diabetic macular edema, postoperative pain, and multiple sclerosis; she has authored numerous primary and secondary market research products on these indications. Ms. Weigel obtained her from Washington and Lee University, where she studied psychology and conducted research in the neuroscience department, and her in pharmaceutical and healthcare business from the University of the Sciences in Philadelphia.

Related Reports

Diabetic Macular Edema / Diabetic Retinopathy | Access & Reimbursement | Detailed, Expanded Analysis: Special Focus on Retinal Therapies: US Payer Management of the Medical Benefit

As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to i...

View Details

Diabetic Macular Edema / Diabetic Retinopathy | Special Topics | Special Topics: Biosimilar Anti-VEGF Agents (US)

The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retin...

View Details